Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy

Mary Cianfrocca, Sandra Lee, Jamie Von Roenn, Anil Tulpule, Bruce J. Dezube, David M. Aboulafia, Richard F Ambinder, Jeannette Y. Lee, Susan E. Krown, Joseph A. Sparano

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined. METHODS: Patients with advanced HIV-associated KS were randomly assigned to receive paclitaxel at a dose of 100 mg/m2 intravenously (iv) every 2 weeks or PLD at a dose of 20 mg/m2 iv every 3 weeks. The KS Functional Assessment of HIV (FAHI) quality of life instrument was used before and after every other treatment cycle. RESULTS: The study included 73 analyzable patients enrolled between 1998 and 2002, including 36 in the paclitaxel arm and 37 in the PLD arm; 73% of patients received highly active antiretroviral therapy (HAART) and 32% had an undetectable viral load (

Original languageEnglish (US)
Pages (from-to)3969-3977
Number of pages9
JournalCancer
Volume116
Issue number16
DOIs
StatePublished - Aug 15 2010

Fingerprint

Kaposi's Sarcoma
Paclitaxel
HIV
Drug Therapy
Quality of Life
Highly Active Antiretroviral Therapy
Cytotoxins
Viral Load
Therapeutics
liposomal doxorubicin

Keywords

  • Acquired immunodeficiency syndrome (AIDS)
  • Human immunodeficiency virus (HIV) infection
  • Kaposi sarcoma
  • Paclitaxel
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma : Evidence of symptom palliation from chemotherapy. / Cianfrocca, Mary; Lee, Sandra; Von Roenn, Jamie; Tulpule, Anil; Dezube, Bruce J.; Aboulafia, David M.; Ambinder, Richard F; Lee, Jeannette Y.; Krown, Susan E.; Sparano, Joseph A.

In: Cancer, Vol. 116, No. 16, 15.08.2010, p. 3969-3977.

Research output: Contribution to journalArticle

Cianfrocca, Mary ; Lee, Sandra ; Von Roenn, Jamie ; Tulpule, Anil ; Dezube, Bruce J. ; Aboulafia, David M. ; Ambinder, Richard F ; Lee, Jeannette Y. ; Krown, Susan E. ; Sparano, Joseph A. / Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma : Evidence of symptom palliation from chemotherapy. In: Cancer. 2010 ; Vol. 116, No. 16. pp. 3969-3977.
@article{b797d6e3f694450c869e7d8a67405edb,
title = "Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy",
abstract = "BACKGROUND: Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined. METHODS: Patients with advanced HIV-associated KS were randomly assigned to receive paclitaxel at a dose of 100 mg/m2 intravenously (iv) every 2 weeks or PLD at a dose of 20 mg/m2 iv every 3 weeks. The KS Functional Assessment of HIV (FAHI) quality of life instrument was used before and after every other treatment cycle. RESULTS: The study included 73 analyzable patients enrolled between 1998 and 2002, including 36 in the paclitaxel arm and 37 in the PLD arm; 73{\%} of patients received highly active antiretroviral therapy (HAART) and 32{\%} had an undetectable viral load (",
keywords = "Acquired immunodeficiency syndrome (AIDS), Human immunodeficiency virus (HIV) infection, Kaposi sarcoma, Paclitaxel, Pegylated liposomal doxorubicin",
author = "Mary Cianfrocca and Sandra Lee and {Von Roenn}, Jamie and Anil Tulpule and Dezube, {Bruce J.} and Aboulafia, {David M.} and Ambinder, {Richard F} and Lee, {Jeannette Y.} and Krown, {Susan E.} and Sparano, {Joseph A.}",
year = "2010",
month = "8",
day = "15",
doi = "10.1002/cncr.25362",
language = "English (US)",
volume = "116",
pages = "3969--3977",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "16",

}

TY - JOUR

T1 - Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma

T2 - Evidence of symptom palliation from chemotherapy

AU - Cianfrocca, Mary

AU - Lee, Sandra

AU - Von Roenn, Jamie

AU - Tulpule, Anil

AU - Dezube, Bruce J.

AU - Aboulafia, David M.

AU - Ambinder, Richard F

AU - Lee, Jeannette Y.

AU - Krown, Susan E.

AU - Sparano, Joseph A.

PY - 2010/8/15

Y1 - 2010/8/15

N2 - BACKGROUND: Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined. METHODS: Patients with advanced HIV-associated KS were randomly assigned to receive paclitaxel at a dose of 100 mg/m2 intravenously (iv) every 2 weeks or PLD at a dose of 20 mg/m2 iv every 3 weeks. The KS Functional Assessment of HIV (FAHI) quality of life instrument was used before and after every other treatment cycle. RESULTS: The study included 73 analyzable patients enrolled between 1998 and 2002, including 36 in the paclitaxel arm and 37 in the PLD arm; 73% of patients received highly active antiretroviral therapy (HAART) and 32% had an undetectable viral load (

AB - BACKGROUND: Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined. METHODS: Patients with advanced HIV-associated KS were randomly assigned to receive paclitaxel at a dose of 100 mg/m2 intravenously (iv) every 2 weeks or PLD at a dose of 20 mg/m2 iv every 3 weeks. The KS Functional Assessment of HIV (FAHI) quality of life instrument was used before and after every other treatment cycle. RESULTS: The study included 73 analyzable patients enrolled between 1998 and 2002, including 36 in the paclitaxel arm and 37 in the PLD arm; 73% of patients received highly active antiretroviral therapy (HAART) and 32% had an undetectable viral load (

KW - Acquired immunodeficiency syndrome (AIDS)

KW - Human immunodeficiency virus (HIV) infection

KW - Kaposi sarcoma

KW - Paclitaxel

KW - Pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=77956861383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956861383&partnerID=8YFLogxK

U2 - 10.1002/cncr.25362

DO - 10.1002/cncr.25362

M3 - Article

C2 - 20564162

AN - SCOPUS:77956861383

VL - 116

SP - 3969

EP - 3977

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 16

ER -